LBCL: Bispecific Antibodies Fare Less Well in Real-World Analysis
In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer outcomes than in clinical trials.
Medscape Medical News
source https://www.medscape.com/viewarticle/lbcl-bispecific-antibodies-fare-less-well-real-world-2024a1000mlg?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/lbcl-bispecific-antibodies-fare-less-well-real-world-2024a1000mlg?src=rss
Comments
Post a Comment